Publicaciones en colaboración con investigadores/as de Hospital del Mar (22)

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients

    Clinical and Experimental Rheumatology

2021

  1. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Influence of the IL17A locus in giant cell arteritis susceptibility

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 9, pp. 1742-1745

2013

  1. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1882-1886

  2. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 7, pp. 1233-1238

2012

  1. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis

    Arthritis Research and Therapy, Vol. 14, Núm. 3

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279

  3. Influence of the IL6 gene in susceptibility to systemic sclerosis

    Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302

2011

  1. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 638-641

  2. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 3, pp. 454-462

  3. The functional polymorphism 844 A>G in Fc αRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility

    Journal of Rheumatology, Vol. 38, Núm. 3, pp. 446-449

2010

  1. Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European study (EUSTAR)

    Journal of Rheumatology, Vol. 37, Núm. 8, pp. 1673-1679

2009

  1. A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 10, pp. 1618-1620